Adverse Selection In The Medicare Prescription Drug Program

Centers for Medicare and Medicaid Services Office of Research, Development, and Information in Baltimore, Maryland, USA.
Health Affairs (Impact Factor: 4.64). 11/2009; 28(6):1826-37. DOI: 10.1377/hlthaff.28.6.1826
Source: PubMed

ABSTRACT The Medicare Part D drug benefit created choices for beneficiaries among many prescription drug plans with varying levels of coverage. As a result, Medicare enrollees with high prescription drug costs have strong incentives to enroll in Part D, especially in plans with more comprehensive coverage. To measure this potential problem of "adverse selection," which could threaten plans' finances, we compared baseline characteristics among groups of beneficiaries with various drug coverage arrangements in 2006. We found some significant differences. For example, enrollees in stand-alone prescription drug plans, especially in plans offering benefits in the coverage gap, or "doughnut hole," had higher baseline drug costs and worse health than enrollees in Medicare Advantage prescription drug plans. Although risk-adjusted payments and other measures have been put in place to account for selection, these patterns could adversely affect future Medicare costs and should be watched carefully.

Download full-text


Available from: Melissa A Evans, Dec 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, the optimal filtering problem for a linear system over observations with a fixed delay is treated, proceeding from the general expression for the stochastic Ito differential of the optimal estimate and its variance. As a result, the optimal filtering equations similar to the traditional Kalman-Bucy filter are obtained in the form dual to the Smith predictor, commonly used control structure for model-based time delay compensation. The paper then presents a robustification algorithm for the obtained optimal filter based on sliding mode compensation of disturbances. As a result, the sliding mode control of observations leading to suppression of the disturbances in a finite time is designed. This control algorithm also guarantees finite-time convergence of the estimate based on the corrupted observations to the optimal estimate satisfying the obtained optimal filtering equations over delayed observations.
    Decision and Control, 2002, Proceedings of the 41st IEEE Conference on; 01/2003
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the introduction of Part D drug benefits, Medicare began to collect information on diagnoses, treatments, and clinical events for millions of beneficiaries. These data are a promising resource for comparative effectiveness research (CER) on treatments, benefit designs, and delivery systems. To explore the data available for researchers and approaches that could be used to enhance the value of Medicare data for CER. CHALLENGES AND OPPORTUNITIES: Using currently available Medicare data for CER is challenging; as with all administrative data, it is not possible to capture every factor that contributes to prescribing decisions and patients are not randomly assigned to treatments. In addition, Part D plan selection and switching may influence treatment decisions and contribute to selection bias. Exploiting certain program aspects could address these limitations. For example, ongoing changes in Medicare or plan policies and the random assignment of beneficiaries with Part D low-income subsidies into plans with different formularies could yield natural experiments. Refining policies for time to data release, provision of additional data elements, and linkage with more beneficiary level information would improve the value and usability of these data. Improving the transparency and reproducibility of findings, and potential open access for qualified stakeholders are also important policy considerations. Data needs must be reconciled with current policies and goals. Medicare data provide a rich resource for CER. Leveraging existing program elements, combined with some administrative changes in data availability, could create large data sets for evaluating treatment patterns, spending, and coverage decisions.
    The American journal of managed care 01/2011; 17(7):488-96. · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical guidelines recommend that women with hormone-receptor positive breast cancer receive endocrine therapy (selective estrogen receptor modulators [SERMs] or aromatase inhibitors [AIs]) for five years following diagnosis. To examine utilization and adherence to therapy for SERMs and AIs in Medicare Part D prescription drug plans. Linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data. We identified 15,542 elderly women diagnosed with hormone-receptor positive breast cancer in years 2003-2005 (the latest SEER data at the time of the study) and enrolled in a Part D plan in 2006 or 2007 (the initial years of Part D). This permitted us to compare utilization and adherence to therapy at various points within the recommended five-year timeframe for endocrine therapy. SERM and AI use was measured from claim records. Non-adherence to therapy was defined as a medication possession ratio of less than 80 percent. Between May 2006 and December 2007, 22 percent of beneficiaries received SERM, 52 percent AI, and 26 percent received neither. The percent receiving any endocrine therapy decreased with time from diagnosis. Among SERM and AI users, 20-30 percent were non-adherent to therapy; out-of-pocket costs were higher for AI than SERM and were strongly associated with non-adherence. For AI users without a low income subsidy, adherence to therapy deteriorated after reaching the Part D coverage gap. Many elderly breast cancer patients were not receiving therapy for the recommended five years following diagnosis. Choosing a Part D plan that minimizes out-of-pocket costs is critical to ensuring beneficiary access to essential medications.
    01/2011; 1(4). DOI:10.5600/mmrr.001.04.a04
Show more